The effects of 18 monoclonal antibodies (α-GPIb, α-GPIIb-IIIa, α-gp78, and α-p151) on platelet function were examined. Four anti-GPIIb-IIIa antibodies and twelve anti-GPIb antibodies were classified into two groups depending on their binding specificities in assays of antibody binding blocking. Of the four anti-GPIIb-IIIa antibodies, three completely inhibited platelet aggregation induced with ADP or collagen, while the other caused only partial inhibition. The first three antibodies showed identical specificity in antibody binding blocking assays. Of the twelve anti-GPIb antibodies, 4 completely inhibited platelet aggregation induced with ristocetin, 2 inhibited it partially, and the other 6 antibodies did not inhibit it at all. No direct correlation was observed between the ability of the antibodies to inhibit platelet aggregation and their binding specificities. The monoclonal antibodies anti-gp78 and anti-pl51 did not affect any of the platelet functions examined.

Keywords:
GPIb, GPIIIb-IIIa, Monoclonal antibodies, Platelets
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.